Ivermectin 400 micrograms/kg: long-term suppression of microfilariae in Bancroftian filariasis.
Identifieur interne : 005609 ( PubMed/Curation ); précédent : 005608; suivant : 005610Ivermectin 400 micrograms/kg: long-term suppression of microfilariae in Bancroftian filariasis.
Auteurs : J P Moulia-Pelat ; P. Glaziou ; L N Nguyen ; S. Chanteau ; R. Plichart ; I. Beylier ; P M Martin ; J L CartelSource :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ]
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Calendrier d'administration des médicaments, Facteurs temps, Filariose lymphatique (traitement médicamenteux), Humains, Ivermectine (administration et posologie), Ivermectine (usage thérapeutique), Porteur sain (traitement médicamenteux), Récidive, Wuchereria bancrofti.
- MESH :
- administration et posologie : Ivermectine.
- traitement médicamenteux : Filariose lymphatique, Porteur sain.
- usage thérapeutique : Ivermectine.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Calendrier d'administration des médicaments, Facteurs temps, Humains, Récidive, Wuchereria bancrofti.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Ivermectin.
- drug therapy : Carrier State, Elephantiasis, Filarial.
- chemical , therapeutic use : Ivermectin.
- Adolescent, Adult, Animals, Drug Administration Schedule, Humans, Middle Aged, Recurrence, Time Factors, Wuchereria bancrofti.
Abstract
Forty-three Wuchereria bancrofti carriers were given 4 successive semi-annual single doses of ivermectin 100 micrograms/kg (IVER 100). The geometric mean microfilaremia (mf) recurrence percentages, compared to the pre-initial treatment mf level, were 35%, 21%, 17% and 17% at 6, 12, 18 and 24 months respectively. However, the recurrence of mf 6 months after the fourth treatment remained high in 15 individuals, considered as 'bad responders'. At month 24, the subjects were randomly allocated into 2 groups: the first group was treated with a fifth dose of IVER 100 and the second with a first, single dose of 400 micrograms/kg of ivermectin (IVER 400). At month 30, the mf recurrence percentage was significantly higher in patients treated with IVER 100 than in those receiving IVER 400 (61% vs. 8%, P < 0.05). In the IVER 100 group, 6 of the 8 'bad responders' remained 'bad responders', whereas only 2 of 7 did so in the IVER 400 group. Only 3 additional patients in the IVER 100 group became consistently amicrofilaraemic, whereas 9 did so in the IVER 400 group. Two 'good responders' in the IVER 100 group became 'bad responders'. A single dose of 400 micrograms/kg of ivermectin has been demonstrated to be efficient for the treatment of carriers refractory to repeated doses of 100 micrograms/kg and to result in better long-term mf suppression. These results suggest a possible effect of 400 micrograms/kg of ivermectin on macrofilaria.
PubMed: 8153984
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005609
Links to Exploration step
pubmed:8153984Curation
No country items
J P Moulia-Pelat<affiliation><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, B.P., Tahiti, Polynése Française.</nlm:affiliation><wicri:noCountry code="subField">Polynése Française</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ivermectin 400 micrograms/kg: long-term suppression of microfilariae in Bancroftian filariasis.</title><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name><affiliation><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, B.P., Tahiti, Polynése Française.</nlm:affiliation><wicri:noCountry code="subField">Polynése Française</wicri:noCountry></affiliation></author><author><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name></author><author><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></author><author><name sortKey="Chanteau, S" sort="Chanteau, S" uniqKey="Chanteau S" first="S" last="Chanteau">S. Chanteau</name></author><author><name sortKey="Plichart, R" sort="Plichart, R" uniqKey="Plichart R" first="R" last="Plichart">R. Plichart</name></author><author><name sortKey="Beylier, I" sort="Beylier, I" uniqKey="Beylier I" first="I" last="Beylier">I. Beylier</name></author><author><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name></author><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1994 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:8153984</idno><idno type="pmid">8153984</idno><idno type="wicri:Area/PubMed/Corpus">005609</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005609</idno><idno type="wicri:Area/PubMed/Curation">005609</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005609</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ivermectin 400 micrograms/kg: long-term suppression of microfilariae in Bancroftian filariasis.</title><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name><affiliation><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, B.P., Tahiti, Polynése Française.</nlm:affiliation><wicri:noCountry code="subField">Polynése Française</wicri:noCountry></affiliation></author><author><name sortKey="Glaziou, P" sort="Glaziou, P" uniqKey="Glaziou P" first="P" last="Glaziou">P. Glaziou</name></author><author><name sortKey="Nguyen, L N" sort="Nguyen, L N" uniqKey="Nguyen L" first="L N" last="Nguyen">L N Nguyen</name></author><author><name sortKey="Chanteau, S" sort="Chanteau, S" uniqKey="Chanteau S" first="S" last="Chanteau">S. Chanteau</name></author><author><name sortKey="Plichart, R" sort="Plichart, R" uniqKey="Plichart R" first="R" last="Plichart">R. Plichart</name></author><author><name sortKey="Beylier, I" sort="Beylier, I" uniqKey="Beylier I" first="I" last="Beylier">I. Beylier</name></author><author><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name></author><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name></author></analytic><series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title><idno type="ISSN">0035-9203</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Carrier State (drug therapy)</term><term>Drug Administration Schedule</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (therapeutic use)</term><term>Middle Aged</term><term>Recurrence</term><term>Time Factors</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Calendrier d'administration des médicaments</term><term>Facteurs temps</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Porteur sain (traitement médicamenteux)</term><term>Récidive</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carrier State</term><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term><term>Porteur sain</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Drug Administration Schedule</term><term>Humans</term><term>Middle Aged</term><term>Recurrence</term><term>Time Factors</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Calendrier d'administration des médicaments</term><term>Facteurs temps</term><term>Humains</term><term>Récidive</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Forty-three Wuchereria bancrofti carriers were given 4 successive semi-annual single doses of ivermectin 100 micrograms/kg (IVER 100). The geometric mean microfilaremia (mf) recurrence percentages, compared to the pre-initial treatment mf level, were 35%, 21%, 17% and 17% at 6, 12, 18 and 24 months respectively. However, the recurrence of mf 6 months after the fourth treatment remained high in 15 individuals, considered as 'bad responders'. At month 24, the subjects were randomly allocated into 2 groups: the first group was treated with a fifth dose of IVER 100 and the second with a first, single dose of 400 micrograms/kg of ivermectin (IVER 400). At month 30, the mf recurrence percentage was significantly higher in patients treated with IVER 100 than in those receiving IVER 400 (61% vs. 8%, P < 0.05). In the IVER 100 group, 6 of the 8 'bad responders' remained 'bad responders', whereas only 2 of 7 did so in the IVER 400 group. Only 3 additional patients in the IVER 100 group became consistently amicrofilaraemic, whereas 9 did so in the IVER 400 group. Two 'good responders' in the IVER 100 group became 'bad responders'. A single dose of 400 micrograms/kg of ivermectin has been demonstrated to be efficient for the treatment of carriers refractory to repeated doses of 100 micrograms/kg and to result in better long-term mf suppression. These results suggest a possible effect of 400 micrograms/kg of ivermectin on macrofilaria.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8153984</PMID><DateCreated><Year>1994</Year><Month>05</Month><Day>10</Day></DateCreated><DateCompleted><Year>1994</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-9203</ISSN><JournalIssue CitedMedium="Print"><Volume>88</Volume><Issue>1</Issue><PubDate><MedlineDate>1994 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Transactions of the Royal Society of Tropical Medicine and Hygiene</Title><ISOAbbreviation>Trans. R. Soc. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>Ivermectin 400 micrograms/kg: long-term suppression of microfilariae in Bancroftian filariasis.</ArticleTitle><Pagination><MedlinePgn>107-9</MedlinePgn></Pagination><Abstract><AbstractText>Forty-three Wuchereria bancrofti carriers were given 4 successive semi-annual single doses of ivermectin 100 micrograms/kg (IVER 100). The geometric mean microfilaremia (mf) recurrence percentages, compared to the pre-initial treatment mf level, were 35%, 21%, 17% and 17% at 6, 12, 18 and 24 months respectively. However, the recurrence of mf 6 months after the fourth treatment remained high in 15 individuals, considered as 'bad responders'. At month 24, the subjects were randomly allocated into 2 groups: the first group was treated with a fifth dose of IVER 100 and the second with a first, single dose of 400 micrograms/kg of ivermectin (IVER 400). At month 30, the mf recurrence percentage was significantly higher in patients treated with IVER 100 than in those receiving IVER 400 (61% vs. 8%, P < 0.05). In the IVER 100 group, 6 of the 8 'bad responders' remained 'bad responders', whereas only 2 of 7 did so in the IVER 400 group. Only 3 additional patients in the IVER 100 group became consistently amicrofilaraemic, whereas 9 did so in the IVER 400 group. Two 'good responders' in the IVER 100 group became 'bad responders'. A single dose of 400 micrograms/kg of ivermectin has been demonstrated to be efficient for the treatment of carriers refractory to repeated doses of 100 micrograms/kg and to result in better long-term mf suppression. These results suggest a possible effect of 400 micrograms/kg of ivermectin on macrofilaria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moulia-Pelat</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Institut Territorial de Recherches Médicales Louis Malardé, B.P., Tahiti, Polynése Française.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaziou</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Chanteau</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Plichart</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Beylier</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Cartel</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trans R Soc Trop Med Hyg</MedlineTA><NlmUniqueID>7506129</NlmUniqueID><ISSNLinking>0035-9203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002353" MajorTopicYN="N">Carrier State</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="Y">Wuchereria bancrofti</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8153984</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005609 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 005609 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:8153984
|texte= Ivermectin 400 micrograms/kg: long-term suppression of microfilariae in Bancroftian filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8153984" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |